Half a Century of Antidepressant Drugs

2007 ◽  
Vol 27 (6) ◽  
pp. 555-559 ◽  
Author(s):  
Francisco López-Muñoz ◽  
Cecilio Álamo ◽  
Georg Juckel ◽  
Hans-Jörg Assion
Keyword(s):  
Antidepressant Drugs

Association between body weight and serum concentration of antidepressant drugs

2015 ◽  
Vol 48 (06) ◽  
Author(s):  
B Warrings ◽  
J Deckert ◽  
S Unterecker
Keyword(s):  
Body Weight ◽  
Serum Concentration ◽  
Antidepressant Drugs

Prescribing Pattern of Antidepressant Drugs among General Practitioners and Psychiatrists: a study from Iran

2013 ◽  
Vol 2 (2) ◽  
pp. 0205
Author(s):  
Hamid Reza Motevallyzadeh ◽  
Mohammad Reza Baneshi ◽  
Maryam Rameshk ◽  
Nouzar Nakhaee
Keyword(s):  
General Practitioners ◽  
Antidepressant Drugs ◽  
Prescribing Pattern

scholarly journals Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

2021 ◽  
Vol 14 (5) ◽  
pp. 458
Author(s):  
Barbara Miziak ◽  
Barbara Błaszczyk ◽  
Stanisław J. Czuczwar
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Ischemia ◽  
Neurodegenerative Disorder ◽  
Neuropsychiatric Symptoms ◽  
Antidepressant Drugs ◽  
Cancer Drug ◽  
Novel Treatments ◽  
Close Relationship ◽  
Approved Drugs

Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms. The available pharmacological treatment is of a symptomatic nature and, as such, it does not modify the cause of AD. The currently used drugs to enhance cognition include an N-methyl-d-aspartate receptor antagonist (memantine) and cholinesterase inhibitors. The PUBMED, Medical Subject Heading and Clinical Trials databases were used for searching relevant data. Novel treatments are focused on already approved drugs for other conditions and also searching for innovative drugs encompassing investigational compounds. Among the approved drugs, we investigated, are intranasal insulin (and other antidiabetic drugs: liraglitude, pioglitazone and metformin), bexarotene (an anti-cancer drug and a retinoid X receptor agonist) or antidepressant drugs (citalopram, escitalopram, sertraline, mirtazapine). The latter, especially when combined with antipsychotics (for instance quetiapine or risperidone), were shown to reduce neuropsychiatric symptoms in AD patients. The former enhanced cognition. Procognitive effects may be also expected with dietary antioxidative and anti-inflammatory supplements—curcumin, myricetin, and resveratrol. Considering a close relationship between brain ischemia and AD, they may also reduce post-brain ischemia neurodegeneration. An investigational compound, CN-105 (a lipoprotein E agonist), has a very good profile in AD preclinical studies, and its clinical trial for postoperative dementia is starting soon.

Sign in / Sign up

Export Citation Format

Share Document